
Adherex Technologies Inc. (NASDAQ:FENC – Free Report) – Research analysts at HC Wainwright lifted their FY2026 EPS estimates for shares of Adherex Technologies in a report issued on Wednesday, November 18th. HC Wainwright analyst R. Selvaraju now forecasts that the company will earn $0.34 per share for the year, up from their prior estimate of $0.21. HC Wainwright has a “Buy” rating and a $17.00 price target on the stock. The consensus estimate for Adherex Technologies’ current full-year earnings is $0.32 per share. HC Wainwright also issued estimates for Adherex Technologies’ Q4 2026 earnings at $0.15 EPS, Q1 2027 earnings at $0.17 EPS, Q2 2027 earnings at $0.23 EPS and FY2027 earnings at $1.00 EPS.
Several other equities research analysts also recently commented on the company. B. Riley Financial reiterated a “buy” rating and set a $19.00 target price (up from $18.00) on shares of Adherex Technologies in a report on Monday. Weiss Ratings upgraded shares of Adherex Technologies from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Friday, November 13th. Wedbush boosted their price target on Adherex Technologies from $13.00 to $16.00 and gave the company an “outperform” rating in a report on Wednesday, August 12th. Finally, Zacks Research raised Adherex Technologies from a “hold” rating to a “strong-buy” rating in a report on Thursday, November 12th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $17.50.
Get Our Latest Stock Analysis on Adherex Technologies
Adherex Technologies Stock Up 0.9%
Adherex Technologies stock opened at $13.45 on Friday. Adherex Technologies has a 52-week low of $5.65 and a 52-week high of $13.85. The firm has a market capitalization of $473.71 million, a P/E ratio of 190.43 and a beta of 1.29. The firm has a fifty day moving average of $10.75 and a 200-day moving average of $9.47.
Adherex Technologies (NASDAQ:FENC – Get Free Report) last posted its quarterly earnings results on Thursday, November 12th. The company reported $0.12 EPS for the quarter, beating the consensus estimate of $0.10 by $0.02. Adherex Technologies had a net margin of 2.52% and a return on equity of 8.96%. The firm had revenue of $19.61 million for the quarter, compared to analyst estimates of $18.87 million.
Insider Activity
In other news, CFO Robert Andrade sold 75,000 shares of the firm’s stock in a transaction dated Thursday, August 27th. The shares were sold at an average price of $11.78, for a total transaction of $883,500.00. Following the completion of the transaction, the chief financial officer owned 217,675 shares in the company, valued at approximately $2,564,211.50. This trade represents a 25.63% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Pierre Sargis Sayad sold 12,000 shares of Adherex Technologies stock in a transaction that occurred on Monday, August 31st. The stock was sold at an average price of $12.18, for a total transaction of $146,160.00. Following the completion of the transaction, the insider directly owned 9,519 shares in the company, valued at $115,941.42. This represents a 55.76% decrease in their position. The SEC filing for this sale provides additional information. 10.73% of the stock is currently owned by insiders.
Adherex Technologies Company Profile
Adherex Technologies was a biotechnology company focused on developing treatments for cancer. In 2014, the company changed its name to Fennec Pharmaceuticals Inc.; Fennec later adopted the Nasdaq ticker FENC. Fennec is a commercial-stage biopharmaceutical company focused on therapies that address complications of cancer treatment. Its principal product is PEDMARK, a sodium thiosulfate injection approved in the United States to reduce the risk of cisplatin-related hearing damage in certain pediatric patients with cancer.
See Also
- Five stocks we like better than Adherex Technologies
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Adherex Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adherex Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
